Replies to post #143879 on Biotech Values

[DewDiligence]

Re: Thrice-weekly Copaxone

Do you think patients will have a say? I mean, if they ask for the more convenient formulation.

A small say at most, IMO—I doubt that many MS patients will even know about the new Copaxone option unless they are made aware of it by their neuro.

Moreover, I question whether a 3x per week dosing schedule for a subcutaneous drug is significantly more convenient than a daily one. If the new drug were weekly, that would be a pretty big deal, but thrice-weekly doesn’t gain much in convenience, IMO.

What do you think?